On Wednesday, Exelixis received an upgrade to its Relative Strength (RS) Rating, from 73 to 81.
Risk Management In The Stock Market: How Much Money To Invest Now
This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against that of all other stocks.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 as they launch their biggest climbs.
Exelixis is not currently near a potential buy zone. See if the stock goes on to build a promising consolidation that could kick off a new price move.
The company reported negative growth for both sales and earnings last quarter.
The company holds the No. 23 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
